Schizophrenia/Psychosis

The chief medical officer of Karuna shares his thoughts exclusively with Psychiatric Times.

Millions of Americans will suffer brain injuries this year, and many of them will need a psychiatrist’s help.

Is it possible to use cognitive testing, which is brief, easily performed, reliable, and noninvasive, to identify individuals at risk for psychosis?

How do men versus women with schizophrenia fare clinically, functionally, and neuropsychologically over the long term?

Selfhood: a complex and continuously evolving identity that is anchored in the patient's history and dependent on language and memory. But there is so much more.

Although the clinical symptoms of psychotic disorders are dramatic and are what most clinicians focus on as their treatment targets, impairments in a wide range of cognitive function are observed in these illnesses.

The first-and-only transdermal patch for adults with schizophrenia offers a new treatment.

Be on the lookout for these novel psychoactive substances.

Preliminary studies suggest that adjuvant treatment with a statin may be beneficial for patients who are also prescribed psychotropic drugs for depression and schizophrenia.

How can the best insights of mainstream and critical psychiatry be brought together?

The RISE study results look promising.

There is much to look forward to in the realm of improved treatments for patients with psychiatric illness.

Our basic science knowledge of the brain continues to explode beyond what science fiction of the past has predicted.

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Navigating the treatment options for comorbid schizophrenia and alcohol use

Findings bring us closer to understanding schizophrenia that may enable clinicians to target symptoms.

Karuna Therapeutics shared exciting results from a Phase 2 trial on their lead agent.

Mutations in PCM1, a gene crucial to neuronal cilia function, have been connected with schizophrenia, according to a recent study.

Listen to discussion on results from a recent Phase 1b clinical trial.

Joining together to discuss psychosis, 3 British experts discuss various ways to respond to and help people who have experienced both trauma and psychosis.

A recent drug trial yields encouraging results.

COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.

Recent research sheds light on the role of adjunctive long-acting injectable antipsychotics in treatment-resistant schizophrenia.

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.